Interferon-beta  ||| S:0 E:16 ||| NNP
and  ||| S:16 E:20 ||| CC
disability  ||| S:20 E:31 ||| JJ
progression  ||| S:31 E:43 ||| NN
in  ||| S:43 E:46 ||| IN
relapsing-remitting  ||| S:46 E:66 ||| JJ
multiple  ||| S:66 E:75 ||| JJ
sclerosis  ||| S:75 E:85 ||| NN
To  ||| S:85 E:88 ||| TO
assess  ||| S:88 E:95 ||| VB
the  ||| S:95 E:99 ||| DT
impact  ||| S:99 E:106 ||| NN
of  ||| S:106 E:109 ||| IN
interferon  ||| S:109 E:120 ||| NNS
( ||| S:120 E:121 ||| -LRB-
IFN ||| S:121 E:124 ||| NNP
) ||| S:124 E:125 ||| -RRB-
-beta  ||| S:125 E:131 ||| JJ
treatment  ||| S:131 E:141 ||| NN
on  ||| S:141 E:144 ||| IN
the  ||| S:144 E:148 ||| DT
progression  ||| S:148 E:160 ||| NN
of  ||| S:160 E:163 ||| IN
unremitting  ||| S:163 E:175 ||| JJ
disability  ||| S:175 E:186 ||| NN
in  ||| S:186 E:189 ||| IN
IFN-beta  ||| S:189 E:198 ||| JJ
treated  ||| S:198 E:206 ||| NN
and  ||| S:206 E:210 ||| CC
untreated  ||| S:210 E:220 ||| JJ
relapsing-remitting  ||| S:220 E:240 ||| NN
( ||| S:240 E:241 ||| -LRB-
RR ||| S:241 E:243 ||| NNP
)  ||| S:243 E:245 ||| -RRB-
patients  ||| S:245 E:254 ||| NNS
with  ||| S:254 E:259 ||| IN
multiple  ||| S:259 E:268 ||| JJ
sclerosis  ||| S:268 E:278 ||| NNS
( ||| S:278 E:279 ||| -LRB-
MS ||| S:279 E:281 ||| NNP
)  ||| S:281 E:283 ||| -RRB-
using  ||| S:283 E:289 ||| VBG
prospective  ||| S:289 E:301 ||| JJ
cohort  ||| S:301 E:308 ||| JJ
study ||| S:308 E:313 ||| NN
.  ||| S:313 E:315 ||| .
A  ||| S:315 E:317 ||| DT
cohort  ||| S:317 E:324 ||| NN
of  ||| S:324 E:327 ||| IN
419  ||| S:327 E:331 ||| CD
RRMS  ||| S:331 E:336 ||| NNP
( ||| S:336 E:337 ||| -LRB-
236  ||| S:337 E:341 ||| CD
IFN-beta-treated  ||| S:341 E:358 ||| JJ
and  ||| S:358 E:362 ||| CC
183  ||| S:362 E:366 ||| CD
untreated ||| S:366 E:375 ||| CD
)  ||| S:375 E:377 ||| -RRB-
patients  ||| S:377 E:386 ||| NNS
was  ||| S:386 E:390 ||| VBD
followed  ||| S:390 E:399 ||| VBN
for  ||| S:399 E:403 ||| IN
up  ||| S:403 E:406 ||| RB
to  ||| S:406 E:409 ||| TO
7  ||| S:409 E:411 ||| CD
years ||| S:411 E:416 ||| NNS
.  ||| S:416 E:418 ||| .
Cox  ||| S:418 E:422 ||| NNP
proportional  ||| S:422 E:435 ||| JJ
hazards  ||| S:435 E:443 ||| NNS
regression  ||| S:443 E:454 ||| JJ
models  ||| S:454 E:461 ||| NNS
adjusted  ||| S:461 E:470 ||| VBN
for  ||| S:470 E:474 ||| IN
the  ||| S:474 E:478 ||| DT
number  ||| S:478 E:485 ||| NN
of  ||| S:485 E:488 ||| IN
relapses  ||| S:488 E:497 ||| NN
in  ||| S:497 E:500 ||| IN
the  ||| S:500 E:504 ||| DT
last  ||| S:504 E:509 ||| JJ
year  ||| S:509 E:514 ||| NN
before  ||| S:514 E:521 ||| IN
first  ||| S:521 E:527 ||| JJ
visit  ||| S:527 E:533 ||| NN
was  ||| S:533 E:537 ||| VBD
used  ||| S:537 E:542 ||| VBN
to  ||| S:542 E:545 ||| TO
assess  ||| S:545 E:552 ||| VB
the  ||| S:552 E:556 ||| DT
differences  ||| S:556 E:568 ||| NNS
between  ||| S:568 E:576 ||| IN
the  ||| S:576 E:580 ||| DT
two  ||| S:580 E:584 ||| CD
groups  ||| S:584 E:591 ||| NNS
for  ||| S:591 E:595 ||| IN
the  ||| S:595 E:599 ||| DT
three  ||| S:599 E:605 ||| CD
end  ||| S:605 E:609 ||| NN
points ||| S:609 E:615 ||| NNS
:  ||| S:615 E:617 ||| :
secondary  ||| S:617 E:627 ||| JJ
progression  ||| S:627 E:639 ||| NNS
( ||| S:639 E:640 ||| -LRB-
SP ||| S:640 E:642 ||| NNP
) ||| S:642 E:643 ||| -RRB-
,  ||| S:643 E:645 ||| ,
and  ||| S:645 E:649 ||| CC
sustained  ||| S:649 E:659 ||| VBD
Expanded  ||| S:659 E:668 ||| NNP
Disability  ||| S:668 E:679 ||| NNP
Status  ||| S:679 E:686 ||| NNP
Scale  ||| S:686 E:692 ||| NNP
( ||| S:692 E:693 ||| -LRB-
EDSS ||| S:693 E:697 ||| NNP
)  ||| S:697 E:699 ||| -RRB-
score  ||| S:699 E:705 ||| VBP
4  ||| S:705 E:707 ||| CD
and  ||| S:707 E:711 ||| CC
6 ||| S:711 E:712 ||| CD
.  ||| S:712 E:714 ||| .
Time  ||| S:714 E:719 ||| NN
from  ||| S:719 E:724 ||| IN
disease  ||| S:724 E:732 ||| NN
onset  ||| S:732 E:738 ||| NN
was  ||| S:738 E:742 ||| VBD
used  ||| S:742 E:747 ||| VBN
as  ||| S:747 E:750 ||| IN
survival  ||| S:750 E:759 ||| NN
time  ||| S:759 E:764 ||| NN
variable ||| S:764 E:772 ||| NN
.  ||| S:772 E:774 ||| .
The  ||| S:774 E:778 ||| DT
IFN-beta-treated  ||| S:778 E:795 ||| JJ
group  ||| S:795 E:801 ||| NN
showed  ||| S:801 E:808 ||| VBD
a  ||| S:808 E:810 ||| DT
highly  ||| S:810 E:817 ||| RB
significant  ||| S:817 E:829 ||| JJ
reduction  ||| S:829 E:839 ||| NN
( ||| S:839 E:840 ||| -LRB-
hazard  ||| S:840 E:847 ||| NN
ratio  ||| S:847 E:853 ||| NN
[ ||| S:853 E:854 ||| -LRB-
HR ||| S:854 E:856 ||| NNP
] ||| S:856 E:857 ||| -RRB-
,  ||| S:857 E:859 ||| ,
0.34 ||| S:859 E:863 ||| NNP
,  ||| S:863 E:865 ||| ,
95 ||| S:865 E:867 ||| CD
%  ||| S:867 E:869 ||| NN
confidence  ||| S:869 E:880 ||| NN
interval  ||| S:880 E:889 ||| NNS
[ ||| S:889 E:890 ||| -LRB-
CI ||| S:890 E:892 ||| NNP
]  ||| S:892 E:894 ||| -RRB-
0.19-0.61 ||| S:894 E:903 ||| NNP
,  ||| S:903 E:905 ||| ,
p  ||| S:905 E:906 ||| CD
< ||| S:906 E:907 ||| SYM
0.001 ||| S:907 E:912 ||| CD
)  ||| S:912 E:914 ||| -RRB-
in  ||| S:914 E:917 ||| IN
the  ||| S:917 E:921 ||| DT
risk  ||| S:921 E:926 ||| NN
of  ||| S:926 E:929 ||| IN
SP  ||| S:929 E:932 ||| NNP
when  ||| S:932 E:937 ||| WRB
compared  ||| S:937 E:946 ||| VBN
with  ||| S:946 E:951 ||| IN
untreated  ||| S:951 E:961 ||| JJ
patients ||| S:961 E:969 ||| NNS
.  ||| S:969 E:971 ||| .
There  ||| S:971 E:977 ||| EX
were  ||| S:977 E:982 ||| VBD
significant  ||| S:982 E:994 ||| JJ
differences  ||| S:994 E:1006 ||| NNS
in  ||| S:1006 E:1009 ||| IN
favor  ||| S:1009 E:1015 ||| NN
of  ||| S:1015 E:1018 ||| IN
the  ||| S:1018 E:1022 ||| DT
IFN-beta-treated  ||| S:1022 E:1039 ||| JJ
group  ||| S:1039 E:1045 ||| NN
for  ||| S:1045 E:1049 ||| IN
the  ||| S:1049 E:1053 ||| DT
end  ||| S:1053 E:1057 ||| NN
point  ||| S:1057 E:1063 ||| NN
EDSS  ||| S:1063 E:1068 ||| NNP
score  ||| S:1068 E:1074 ||| NN
of  ||| S:1074 E:1077 ||| IN
4  ||| S:1077 E:1079 ||| CD
( ||| S:1079 E:1080 ||| -LRB-
HR=0.45 ||| S:1080 E:1087 ||| NNP
,  ||| S:1087 E:1089 ||| ,
95 ||| S:1089 E:1091 ||| CD
% ||| S:1091 E:1092 ||| NN
CI  ||| S:1092 E:1095 ||| NNP
0.28-0.73 ||| S:1095 E:1104 ||| NNP
,  ||| S:1104 E:1106 ||| ,
p=0.001 ||| S:1106 E:1113 ||| CD
)  ||| S:1113 E:1115 ||| -RRB-
and  ||| S:1115 E:1119 ||| CC
EDSS  ||| S:1119 E:1124 ||| NNP
score  ||| S:1124 E:1130 ||| NN
of  ||| S:1130 E:1133 ||| IN
6  ||| S:1133 E:1135 ||| CD
( ||| S:1135 E:1136 ||| -LRB-
HR=0.34 ||| S:1136 E:1143 ||| NNP
,  ||| S:1143 E:1145 ||| ,
95 ||| S:1145 E:1147 ||| CD
% ||| S:1147 E:1148 ||| NN
CI  ||| S:1148 E:1151 ||| NNP
0.16-0.75 ||| S:1151 E:1160 ||| NNP
,  ||| S:1160 E:1162 ||| ,
p=0.007 ||| S:1162 E:1169 ||| CD
) ||| S:1169 E:1170 ||| -RRB-
.  ||| S:1170 E:1172 ||| .
This  ||| S:1172 E:1177 ||| DT
observational  ||| S:1177 E:1191 ||| JJ
study  ||| S:1191 E:1197 ||| NN
further  ||| S:1197 E:1205 ||| RB
supports  ||| S:1205 E:1214 ||| VBZ
the  ||| S:1214 E:1218 ||| DT
notion  ||| S:1218 E:1225 ||| NN
that  ||| S:1225 E:1230 ||| IN
IFN-beta  ||| S:1230 E:1239 ||| NNP
could  ||| S:1239 E:1245 ||| MD
have  ||| S:1245 E:1250 ||| VB
potential  ||| S:1250 E:1260 ||| JJ
beneficial  ||| S:1260 E:1271 ||| JJ
effect  ||| S:1271 E:1278 ||| NN
on  ||| S:1278 E:1281 ||| IN
disease  ||| S:1281 E:1289 ||| NN
progression  ||| S:1289 E:1301 ||| NN
in  ||| S:1301 E:1304 ||| IN
RRMS ||| S:1304 E:1308 ||| NNP
.  ||| S:1308 E:1310 ||| .
